Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
- PMID: 31722150
- DOI: 10.1056/NEJMoa1817307
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
Abstract
Background: Many countries have stockpiled vaccines because of concerns about the reemergence of smallpox. Traditional smallpox vaccines are based on replicating vaccinia viruses; these vaccines have considerable side effects.
Methods: To evaluate the efficacy of modified vaccinia Ankara (MVA) as a potential smallpox vaccine, we randomly assigned 440 participants to receive two doses of MVA followed by one dose of the established replicating-vaccinia vaccine ACAM2000 (the MVA group) or to receive one dose of ACAM2000 (the ACAM2000-only group). The two primary end points were noninferiority of the MVA vaccine to ACAM2000 with respect to the peak serum neutralizing antibody titers and attenuation of the ACAM2000-associated major cutaneous reaction by previous MVA vaccination, measured according to the maximum lesion area and the derived area attenuation ratio.
Results: A total of 220 and 213 participants were randomly assigned and vaccinated in the MVA group and ACAM2000-only group, respectively, and 208 participants received two MVA vaccinations. At peak visits, MVA vaccination induced a geometric mean titer of neutralizing antibodies of 153.5 at week 6, as compared with 79.3 at week 4 with ACAM2000 (a ratio of 1.94 [95% confidence interval {CI}, 1.56 to 2.40]). At day 14, the geometric mean titer of neutralizing antibodies induced by a single MVA vaccination (16.2) was equal to that induced by ACAM2000 (16.2), and the percentages of participants with seroconversion were similar (90.8% and 91.8%, respectively). The median lesion areas of the major cutaneous reaction were 0 mm2 in the MVA group and 76.0 mm2 in the ACAM2000-only group, resulting in an area attenuation ratio of 97.9% (95% CI, 96.6 to 98.3). There were fewer adverse events or adverse events of grade 3 or higher after both MVA vaccination periods in the MVA group than in the ACAM2000-only group (17 vs. 64 participants with adverse events of grade 3 or higher, P<0.001).
Conclusions: No safety concerns associated with the MVA vaccine were identified. Immune responses and attenuation of the major cutaneous reaction suggest that this MVA vaccine protected against variola infection. (Funded by the Office of the Assistant Secretary for Preparedness and Response Biomedical Advanced Research and Development Authority of the Department of Health and Human Services and Bavarian Nordic; ClinicalTrials.gov number, NCT01913353.).
Copyright © 2019 Massachusetts Medical Society.
Comment in
-
On the "Take" as a Biomarker.N Engl J Med. 2019 Nov 14;381(20):1962-1963. doi: 10.1056/NEJMe1913048. N Engl J Med. 2019. PMID: 31722158 No abstract available.
-
A Modified Vaccine against Smallpox.N Engl J Med. 2020 Mar 26;382(13):1285. doi: 10.1056/NEJMc2001156. N Engl J Med. 2020. PMID: 32212533 No abstract available.
Similar articles
-
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7. J Infect Dis. 2013. PMID: 23225902 Free PMC article.
-
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.Virology. 2005 Sep 1;339(2):164-75. doi: 10.1016/j.virol.2005.06.002. Virology. 2005. PMID: 15993917
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016. PLoS One. 2016. PMID: 27327616 Free PMC article. Clinical Trial.
-
IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13. Expert Rev Vaccines. 2009. PMID: 19093767 Free PMC article. Review.
-
Clinical development of Modified Vaccinia virus Ankara vaccines.Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Vaccine. 2013. PMID: 23523410 Review.
Cited by
-
Current Status of Vaccine Development for Monkeypox Virus.Adv Exp Med Biol. 2024;1451:289-300. doi: 10.1007/978-3-031-57165-7_18. Adv Exp Med Biol. 2024. PMID: 38801585 Review.
-
Poxviridae Pneumonia.Adv Exp Med Biol. 2024;1451:183-204. doi: 10.1007/978-3-031-57165-7_12. Adv Exp Med Biol. 2024. PMID: 38801579 Review.
-
Monkeypox: From Emerging Trends to Therapeutic Concerns.Cureus. 2024 Apr 23;16(4):e58866. doi: 10.7759/cureus.58866. eCollection 2024 Apr. Cureus. 2024. PMID: 38800170 Free PMC article. Review.
-
Factors potentially contributing to the decline of the mpox outbreak in the Netherlands, 2022 and 2023.Euro Surveill. 2024 May;29(21):2300608. doi: 10.2807/1560-7917.ES.2024.29.21.2300608. Euro Surveill. 2024. PMID: 38785092 Free PMC article.
-
Predicting vaccine effectiveness for mpox.Nat Commun. 2024 May 8;15(1):3856. doi: 10.1038/s41467-024-48180-w. Nat Commun. 2024. PMID: 38719852 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical